阴性乳腺癌-话题@MedSci

#阴性乳腺癌#

226篇内容 | 3202人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2048092, encodeId=2750204809247, content=<a href='/topic/show?id=12e49e53102' target=_blank style='color:#2F92EE;'>#阴性乳腺癌#</a>, objectTitle=JNCI：三种PD-L1免疫组化分析方法对比及与三阴性乳腺癌患者治疗预后的相关性, objectType=article, longId=212568, objectId=05fd212568c8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=05fd212568c8, replyNumber=0, likeNumber=0, createdTime=2022-02-20, rootId=0, userName=circumcision, userId=f65b226, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=05fd212568c8, moduleTitle=JNCI：三种PD-L1免疫组化分析方法对比及与三阴性乳腺癌患者治疗预后的相关性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=05fd212568c8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2048073, encodeId=aa6520480e3e4, content=<a href='/topic/show?id=12e49e53102' target=_blank style='color:#2F92EE;'>#阴性乳腺癌#</a>, objectTitle=Br J Cancer：新型AMPK激活剂SU212诱导细胞氧化磷酸化抑制三阴性乳腺癌的发生发展, objectType=article, longId=203367, objectId=927e20336e88, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=927e20336e88, replyNumber=0, likeNumber=91, createdTime=2021-07-09, rootId=0, userName=circumcision, userId=f65b226, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=927e20336e88, moduleTitle=Br J Cancer：新型AMPK激活剂SU212诱导细胞氧化磷酸化抑制三阴性乳腺癌的发生发展, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=927e20336e88)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2048062, encodeId=fb0e2048062a3, content=<a href='/topic/show?id=12e49e53102' target=_blank style='color:#2F92EE;'>#阴性乳腺癌#</a>, objectTitle=Cancer Discov：三阴性乳腺癌新疗法——BBOX1抑制剂, objectType=article, longId=198615, objectId=fd3c1986155e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fd3c1986155e, replyNumber=0, likeNumber=64, createdTime=2020-08-21, rootId=0, userName=circumcision, userId=f65b226, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fd3c1986155e, moduleTitle=Cancer Discov：三阴性乳腺癌新疗法——BBOX1抑制剂, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fd3c1986155e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2048067, encodeId=9058204806eb4, content=<a href='/topic/show?id=12e49e53102' target=_blank style='color:#2F92EE;'>#阴性乳腺癌#</a>, objectTitle=Cell Death Dis：lncRNA PCAT6促进三阴性乳腺癌的发生和血管生成, objectType=article, longId=200541, objectId=8538200541be, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8538200541be, replyNumber=0, likeNumber=42, createdTime=2021-02-17, rootId=0, userName=circumcision, userId=f65b226, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8538200541be, moduleTitle=Cell Death Dis：lncRNA PCAT6促进三阴性乳腺癌的发生和血管生成, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8538200541be)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2048074, encodeId=4ced20480e4f5, content=<a href='/topic/show?id=12e49e53102' target=_blank style='color:#2F92EE;'>#阴性乳腺癌#</a>, objectTitle=Cell Metab ：邵志敏团队为三阴性乳腺癌“复旦分型”精准治疗策略再添新翼, objectType=article, longId=203440, objectId=ed4520344094, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ed4520344094, replyNumber=0, likeNumber=73, createdTime=2021-03-08, rootId=0, userName=circumcision, userId=f65b226, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ed4520344094, moduleTitle=Cell Metab ：邵志敏团队为三阴性乳腺癌“复旦分型”精准治疗策略再添新翼, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ed4520344094)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2048079, encodeId=d71620480e98e, content=<a href='/topic/show?id=12e49e53102' target=_blank style='color:#2F92EE;'>#阴性乳腺癌#</a>, objectTitle=Ann Oncol：奥拉帕利单一疗法在初治的三阴性乳腺癌患者中的疗效, objectType=article, longId=205899, objectId=a8822058990b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a8822058990b, replyNumber=0, likeNumber=73, createdTime=2021-12-31, rootId=0, userName=circumcision, userId=f65b226, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a8822058990b, moduleTitle=Ann Oncol：奥拉帕利单一疗法在初治的三阴性乳腺癌患者中的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a8822058990b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2048076, encodeId=756920480e6f3, content=<a href='/topic/show?id=12e49e53102' target=_blank style='color:#2F92EE;'>#阴性乳腺癌#</a>, objectTitle=Cell Death Differ：DYRK2激活HSF1增强对蛋白毒性应激反应的抵抗力并促进三阴性乳腺癌的发生发展, objectType=article, longId=204302, objectId=99c5204302ab, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=99c5204302ab, replyNumber=0, likeNumber=47, createdTime=2021-03-05, rootId=0, userName=circumcision, userId=f65b226, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=99c5204302ab, moduleTitle=Cell Death Differ：DYRK2激活HSF1增强对蛋白毒性应激反应的抵抗力并促进三阴性乳腺癌的发生发展, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=99c5204302ab)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2048070, encodeId=3f9220480e0f9, content=<a href='/topic/show?id=12e49e53102' target=_blank style='color:#2F92EE;'>#阴性乳腺癌#</a>, objectTitle=Lancet：阿特珠单抗用于早期三阴性乳腺癌的辅助化疗, objectType=article, longId=201020, objectId=777c201020c6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=777c201020c6, replyNumber=0, likeNumber=70, createdTime=2021-08-16, rootId=0, userName=circumcision, userId=f65b226, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=777c201020c6, moduleTitle=Lancet：阿特珠单抗用于早期三阴性乳腺癌的辅助化疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=777c201020c6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2048054, encodeId=470820480543e, content=<a href='/topic/show?id=12e49e53102' target=_blank style='color:#2F92EE;'>#阴性乳腺癌#</a>, objectTitle=抗体药物偶联物DS-1062研究范围被扩大，治疗晚期或转移性三阴性乳腺癌, objectType=article, longId=196920, objectId=36881969209a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=36881969209a, replyNumber=0, likeNumber=81, createdTime=2020-08-06, rootId=0, userName=circumcision, userId=f65b226, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=36881969209a, moduleTitle=抗体药物偶联物DS-1062研究范围被扩大，治疗晚期或转移性三阴性乳腺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=36881969209a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2048060, encodeId=9c88204806014, content=<a href='/topic/show?id=12e49e53102' target=_blank style='color:#2F92EE;'>#阴性乳腺癌#</a>, objectTitle=Cell Res ：复旦大学发布三阴性乳腺癌精准治疗方案，让患者从山穷水尽到柳暗花明, objectType=article, longId=198326, objectId=2e6f1983269e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2e6f1983269e, replyNumber=0, likeNumber=67, createdTime=2020-10-21, rootId=0, userName=circumcision, userId=f65b226, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2e6f1983269e, moduleTitle=Cell Res ：复旦大学发布三阴性乳腺癌精准治疗方案，让患者从山穷水尽到柳暗花明, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2e6f1983269e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2048051, encodeId=595c204805197, content=<a href='/topic/show?id=12e49e53102' target=_blank style='color:#2F92EE;'>#阴性乳腺癌#</a>, objectTitle=提供大幅折扣后，英国NICE批准了罗氏的PD-L1单抗Tecentriq治疗三阴性乳腺癌, objectType=article, longId=195499, objectId=9c0719549995, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9c0719549995, replyNumber=0, likeNumber=89, createdTime=2020-11-22, rootId=0, userName=circumcision, userId=f65b226, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9c0719549995, moduleTitle=提供大幅折扣后，英国NICE批准了罗氏的PD-L1单抗Tecentriq治疗三阴性乳腺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9c0719549995)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2048058, encodeId=41862048058e0, content=<a href='/topic/show?id=12e49e53102' target=_blank style='color:#2F92EE;'>#阴性乳腺癌#</a>, objectTitle=Clini Cancer Res：PD-L1表达与三阴性乳腺癌新辅助化疗预后的相关性, objectType=article, longId=198067, objectId=a92519806e26, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a92519806e26, replyNumber=0, likeNumber=65, createdTime=2020-10-26, rootId=0, userName=circumcision, userId=f65b226, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a92519806e26, moduleTitle=Clini Cancer Res：PD-L1表达与三阴性乳腺癌新辅助化疗预后的相关性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a92519806e26)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2048059, encodeId=46ff204805965, content=<a href='/topic/show?id=12e49e53102' target=_blank style='color:#2F92EE;'>#阴性乳腺癌#</a>, objectTitle=Cancer Dis：三阴性乳腺癌靶向治疗新突破！BBOX1基因是关键！, objectType=article, longId=198235, objectId=9ec619823514, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9ec619823514, replyNumber=0, likeNumber=57, createdTime=2020-10-21, rootId=0, userName=circumcision, userId=f65b226, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9ec619823514, moduleTitle=Cancer Dis：三阴性乳腺癌靶向治疗新突破！BBOX1基因是关键！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9ec619823514)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2048086, encodeId=2f1c204808633, content=<a href='/topic/show?id=12e49e53102' target=_blank style='color:#2F92EE;'>#阴性乳腺癌#</a>, objectTitle=Br J Cancer：PI3K信号通路激活导致HER2阴性乳腺癌的eribulin耐药性的产生, objectType=article, longId=208867, objectId=cb1020886ea9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cb1020886ea9, replyNumber=0, likeNumber=84, createdTime=2021-04-26, rootId=0, userName=circumcision, userId=f65b226, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cb1020886ea9, moduleTitle=Br J Cancer：PI3K信号通路激活导致HER2阴性乳腺癌的eribulin耐药性的产生, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cb1020886ea9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2048083, encodeId=5d8220480833a, content=<a href='/topic/show?id=12e49e53102' target=_blank style='color:#2F92EE;'>#阴性乳腺癌#</a>, objectTitle=Lancet oncol：3期| 派姆单抗用作转移性三阴性乳腺癌的二三线疗法的疗效, objectType=article, longId=207920, objectId=b4f120e9205b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b4f120e9205b, replyNumber=0, likeNumber=66, createdTime=2021-07-20, rootId=0, userName=circumcision, userId=f65b226, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b4f120e9205b, moduleTitle=Lancet oncol：3期| 派姆单抗用作转移性三阴性乳腺癌的二三线疗法的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b4f120e9205b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2048044, encodeId=9b1a20480445e, content=<a href='/topic/show?id=12e49e53102' target=_blank style='color:#2F92EE;'>#阴性乳腺癌#</a>, objectTitle=AACR 2020：免疫联合治疗在三阴性乳腺癌治疗中获突破，OS高达16个月, objectType=article, longId=193174, objectId=9c411931e4ea, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9c411931e4ea, replyNumber=0, likeNumber=73, createdTime=2021-01-25, rootId=0, userName=circumcision, userId=f65b226, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9c411931e4ea, moduleTitle=AACR 2020：免疫联合治疗在三阴性乳腺癌治疗中获突破，OS高达16个月, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9c411931e4ea)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2048075, encodeId=c15020480e5e6, content=<a href='/topic/show?id=12e49e53102' target=_blank style='color:#2F92EE;'>#阴性乳腺癌#</a>, objectTitle=Lancet：派姆单抗联合化疗一线治疗PD-L1阳性转移性三阴性乳腺癌, objectType=article, longId=204210, objectId=9f312042101b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9f312042101b, replyNumber=0, likeNumber=93, createdTime=2020-12-09, rootId=0, userName=circumcision, userId=f65b226, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9f312042101b, moduleTitle=Lancet：派姆单抗联合化疗一线治疗PD-L1阳性转移性三阴性乳腺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9f312042101b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2048068, encodeId=efc12048068cb, content=<a href='/topic/show?id=12e49e53102' target=_blank style='color:#2F92EE;'>#阴性乳腺癌#</a>, objectTitle=Cell Death Dis：miR-210-3p调控三阴性乳腺癌中的糖酵解作用, objectType=article, longId=200544, objectId=680620054436, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=680620054436, replyNumber=0, likeNumber=42, createdTime=2021-03-28, rootId=0, userName=circumcision, userId=f65b226, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=680620054436, moduleTitle=Cell Death Dis：miR-210-3p调控三阴性乳腺癌中的糖酵解作用, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=680620054436)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2048066, encodeId=49702048066b7, content=<a href='/topic/show?id=12e49e53102' target=_blank style='color:#2F92EE;'>#阴性乳腺癌#</a>, objectTitle=Cell Death Dis：lncRNA LRRC75A-AS1促进三阴性乳腺癌的发生发展, objectType=article, longId=200182, objectId=3566200182bd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3566200182bd, replyNumber=0, likeNumber=70, createdTime=2020-12-31, rootId=0, userName=circumcision, userId=f65b226, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3566200182bd, moduleTitle=Cell Death Dis：lncRNA LRRC75A-AS1促进三阴性乳腺癌的发生发展, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3566200182bd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2048081, encodeId=c26e204808162, content=<a href='/topic/show?id=12e49e53102' target=_blank style='color:#2F92EE;'>#阴性乳腺癌#</a>, objectTitle=AL101治疗Notch信号通路激活的三阴性乳腺癌, objectType=article, longId=206438, objectId=ffec20643896, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ffec20643896, replyNumber=0, likeNumber=73, createdTime=2021-08-17, rootId=0, userName=circumcision, userId=f65b226, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ffec20643896, moduleTitle=AL101治疗Notch信号通路激活的三阴性乳腺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ffec20643896)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

阴性乳腺癌

2020-05-29

circumcision (审核中...)

前往app查看评论内容

#阴性乳腺癌#

JNCI：三种PD-L1免疫组化分析方法对比及与三阴性乳腺癌患者治疗预后的相关性

2022-02-20

circumcision (审核中...)

前往app查看评论内容

#阴性乳腺癌#

Br J Cancer：新型AMPK激活剂SU212诱导细胞氧化磷酸化抑制三阴性乳腺癌的发生发展

2021-07-09

circumcision (审核中...)

前往app查看评论内容

#阴性乳腺癌#

Cancer Discov：三阴性乳腺癌新疗法——BBOX1抑制剂

2020-08-21

circumcision (审核中...)

前往app查看评论内容

#阴性乳腺癌#

Cell Death Dis：lncRNA PCAT6促进三阴性乳腺癌的发生和血管生成

2021-02-17

circumcision (审核中...)

前往app查看评论内容

#阴性乳腺癌#

Cell Metab ：邵志敏团队为三阴性乳腺癌“复旦分型”精准治疗策略再添新翼

2021-03-08

circumcision (审核中...)

前往app查看评论内容

#阴性乳腺癌#

Ann Oncol：奥拉帕利单一疗法在初治的三阴性乳腺癌患者中的疗效

2021-12-31

circumcision (审核中...)

前往app查看评论内容

#阴性乳腺癌#

Cell Death Differ：DYRK2激活HSF1增强对蛋白毒性应激反应的抵抗力并促进三阴性乳腺癌的发生发展

2021-03-05

circumcision (审核中...)

前往app查看评论内容

#阴性乳腺癌#

Lancet：阿特珠单抗用于早期三阴性乳腺癌的辅助化疗

2021-08-16

circumcision (审核中...)

前往app查看评论内容

#阴性乳腺癌#

抗体药物偶联物DS-1062研究范围被扩大，治疗晚期或转移性三阴性乳腺癌

2020-08-06

circumcision (审核中...)

前往app查看评论内容

#阴性乳腺癌#

Cell Res ：复旦大学发布三阴性乳腺癌精准治疗方案，让患者从山穷水尽到柳暗花明

2020-10-21

circumcision (审核中...)

前往app查看评论内容

#阴性乳腺癌#

提供大幅折扣后，英国NICE批准了罗氏的PD-L1单抗Tecentriq治疗三阴性乳腺癌

2020-11-22

circumcision (审核中...)

前往app查看评论内容

#阴性乳腺癌#

Clini Cancer Res：PD-L1表达与三阴性乳腺癌新辅助化疗预后的相关性

2020-10-26

circumcision (审核中...)

前往app查看评论内容

#阴性乳腺癌#

Cancer Dis：三阴性乳腺癌靶向治疗新突破！BBOX1基因是关键！

2020-10-21

circumcision (审核中...)

前往app查看评论内容

#阴性乳腺癌#

Br J Cancer：PI3K信号通路激活导致HER2阴性乳腺癌的eribulin耐药性的产生

2021-04-26

circumcision (审核中...)

前往app查看评论内容

#阴性乳腺癌#

Lancet oncol：3期| 派姆单抗用作转移性三阴性乳腺癌的二三线疗法的疗效

2021-07-20

circumcision (审核中...)

前往app查看评论内容

#阴性乳腺癌#

AACR 2020：免疫联合治疗在三阴性乳腺癌治疗中获突破，OS高达16个月

2021-01-25

circumcision (审核中...)

前往app查看评论内容

#阴性乳腺癌#

Lancet：派姆单抗联合化疗一线治疗PD-L1阳性转移性三阴性乳腺癌

2020-12-09

circumcision (审核中...)

前往app查看评论内容

#阴性乳腺癌#

Cell Death Dis：miR-210-3p调控三阴性乳腺癌中的糖酵解作用

2021-03-28

circumcision (审核中...)

前往app查看评论内容

#阴性乳腺癌#

Cell Death Dis：lncRNA LRRC75A-AS1促进三阴性乳腺癌的发生发展

2020-12-31

circumcision (审核中...)

前往app查看评论内容

#阴性乳腺癌#

AL101治疗Notch信号通路激活的三阴性乳腺癌

2021-08-17

科室
- - 订阅+
  - 更多科室
工具
服务